MedTrace Logo

Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia

NCT07689162 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-08-18

No results posted yet for this study

Summary

The purpose of this study is to find out which pain medication is more effective in reducing pain after nose surgery (rhinoplasty). The investigators are looking to find the best treatment to reduce discomfort and improve the healing process for patients having nose surgery.

Conditions

  • Pain, Postoperative

Interventions

DRUG

Standard Bupivacaine

Volume: 4 mL of 0.75% bupivacaine hydrochloride

DRUG

Liposomal Bupivacaine

Volume: 1.5 mL of 0.75% bupivacaine hydrochloride and 2.5 mL of liposomal bupivacaine

Sponsors & Collaborators

Principal Investigators

  • Matthew Wu, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2027-06-30
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07689162 on ClinicalTrials.gov